- Home
- RDI vs ASBP Comparison
RDI vs ASBP Comparison
Compare RDI & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- ASBP
- Stock Information
- Founded
- RDI 1937
- ASBP 2021
- Country
- RDI United States
- ASBP United States
- Employees
- RDI N/A
- ASBP N/A
- Industry
- RDI Movies/Entertainment
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- ASBP Health Care
- Exchange
- RDI Nasdaq
- ASBP Nasdaq
- Market Cap
- RDI 30.1M
- ASBP 26.6M
- IPO Year
- RDI N/A
- ASBP N/A
- Fundamental
- Price
- RDI $1.25
- ASBP $0.57
- Analyst Decision
- RDI Hold
- ASBP
- Analyst Count
- RDI 1
- ASBP 0
- Target Price
- RDI $2.40
- ASBP N/A
- AVG Volume (30 Days)
- RDI 42.0K
- ASBP 216.1K
- Earning Date
- RDI 05-14-2025
- ASBP 05-24-2025
- Dividend Yield
- RDI N/A
- ASBP N/A
- EPS Growth
- RDI N/A
- ASBP N/A
- EPS
- RDI N/A
- ASBP N/A
- Revenue
- RDI $210,527,000.00
- ASBP N/A
- Revenue This Year
- RDI $11.97
- ASBP N/A
- Revenue Next Year
- RDI $6.40
- ASBP N/A
- P/E Ratio
- RDI N/A
- ASBP N/A
- Revenue Growth
- RDI N/A
- ASBP N/A
- 52 Week Low
- RDI $1.17
- ASBP $0.40
- 52 Week High
- RDI $1.89
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- RDI 45.11
- ASBP N/A
- Support Level
- RDI $1.18
- ASBP N/A
- Resistance Level
- RDI $1.28
- ASBP N/A
- Average True Range (ATR)
- RDI 0.08
- ASBP 0.00
- MACD
- RDI 0.00
- ASBP 0.00
- Stochastic Oscillator
- RDI 25.00
- ASBP 0.00
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract.